Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 1/20 | 0.53 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 18/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3408155 | 0.93 | LATS1 (0.48) | STK17BSTK17ABRD4ADORA2AADORA1 | |
| SCHEMBL3410303 | 0.82 | STK17B (0.49) | STK17BSTK17ABRD4 | |
| SCHEMBL13912909 | 0.79 | ZAP70 (0.38) | BRD4 | |
| SCHEMBL3407462 | 0.79 | STK17B (0.46) | STK17BSTK17ABRD4 | |
| SCHEMBL3408150 | 0.79 | BCHE (0.46) | STK17BSTK17ABRD4 | |
| SCHEMBL13333049 | 0.78 | STK17B (0.51) | STK17BSTK17ABRD4ADORA2AADORA2B | |
| SCHEMBL19707059 | 0.78 | CRHR1 (0.43) | — | |
| SCHEMBL3401324 | 0.77 | PCSK9 (0.37) | STK17BSTK17ABRD4ADORA2AADORA1 | |
| SCHEMBL3401318 | 0.77 | PCSK9 (0.37) | STK17BSTK17ABRD4ADORA2AADORA1 | |
| SCHEMBL2849201 | 0.76 | MTNR1A (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2254887-B9 | OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-8349826-B2 | Oxazolidinone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-01-08 | — | — | US | disclosed |
| EP-2254887-B1 | OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-12-19 | — | — | EP | disclosed |
| US-20100331308-A1 | OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-12-30 | — | — | US | disclosed |
| EP-2254887-A1 | OXAZOLIDINONE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009104159-A1 | OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331308-A1 | OXAZOLIDINONE DERIVATIVES | OXA1L, UQCRB, O60361 | STK17B 929/4885STK17A 1280/4885BRD4 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.